HIMS rebounds on GLP-1 growth and rising earnings estimates, while DXC slumps amid falling sales and eroding investor ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced ...

From a receding hairline to thinning crown and balding, hair loss can be a difficult personal experience for many men as they ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...

The Odisha Government today issued strict instructions to all public and private universities, as well as government and unaided degree colleges under the Higher Education Department, to constitute ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the start.

Ozempic, which is prescribed for diabetes, and Wegovy, prescribed for weight loss, both contain the active ingredient ...

Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.

Bank of America names its highest-conviction stock ideas for Q3 2025—8 Buys and 2 Underperforms. Boeing, Cisco, and Datadog ...

Seeking Alpha's daily roundup of remarks and statements that could impact markets, sectors or individual stocks. Read more ...